SCHEMBL620718

SCHEMBL620718

NC(=O)c1cc(-c2cccs2)cc2c(C3CCCS(O)(O)C3)c[nH]c12

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 20/20 0.61
CHUK O15111 4/20 0.51
CSF1R P07333 1/20 0.51
BTK Q06187 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618253 0.94 IKBKB (0.60) IKBKBCHUKCSF1RBTK
SCHEMBL620717 0.91 IKBKB (0.75) IKBKBCHUKCSF1RBTK
SCHEMBL621283 0.89 IKBKB (0.61) IKBKBCHUKCSF1RBTK
SCHEMBL618254 0.87 IKBKB (0.74) IKBKBCHUKCSF1RBTK
SCHEMBL618686 0.85 IKBKB (0.81) IKBKBCHUKCSF1RBTK
SCHEMBL621282 0.85 IKBKB (0.73) IKBKBCHUKCSF1RBTK
SCHEMBL619348 0.84 IKBKB (0.62) IKBKBCHUKCSF1RBTK
SCHEMBL619023 0.83 IKBKB (0.62) IKBKBCHUKCSF1RBTK
SCHEMBL3800588 0.82 IKBKB (0.72) IKBKBCHUKCSF1RBTK
SCHEMBL14019045 0.82 IKBKB (0.57) IKBKBCHUKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372875-B2 Indole carboxamides as IKK2 inhibitors GlaxoSmithKline, LLC (US) 2013-02-12 US disclosed
US-20120040958-A1 INDOLE CARBOXAMIDES AS IKK2 INHIBITORS GLAXOSMITHKLINE LLC 2012-02-16 US disclosed
US-8071584-B2 Indole carboxamides as IKK2 inhibitors GLAXOSMITHKLINE LLC (US) 2011-12-06 US disclosed
US-20100130468-A1 INDOLE CARBOXAMIDES AS IKK2 INHIBITORS GLAXOSMITHKLINE LLC 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040958-A1 INDOLE CARBOXAMIDES AS IKK2 INHIBITORS IDO2, IDO1, NFKBIA IKBKB 8/4885CHUK 14/4885CSF1R 1350/4885
US-20100130468-A1 INDOLE CARBOXAMIDES AS IKK2 INHIBITORS IDO2, IDO1, NFKBIA IKBKB 8/4885CHUK 14/4885CSF1R 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.